此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

巴甲替尼在治疗肠道综合症中

2026年9月17日 更新者:Peking Union Medical College Hospital

一项多中心,前瞻性,开放标签,随机研究,探索Bariticinib在难治性肠道behçet综合征患者中的功效和安全性

This study aims to conduct a randomized controlled trial to compare the efficacy and safety of Baricitinib and Adalimumab (ADA) in the treatment of refractory intestinal Behçet's Syndrome (BS). The objective is to demonstrate if Baricitinib is non-inferior to ADA in controlling BS inflammation, reducing BS recurrence, alleviating gastrointestinal symptoms and promoting intestinal mucosal healing.

研究概览

详细说明

The non-inferiority will be established by comparing the lower bound of the two-sided 95% confidence interval with the non-inferiority margin. If the lower bound was larger than the margin, Baricitinib would be regarded as non-inferiror to ADA. Superority will be further assessed in case that the non-inferiority is established. Both ITT and PP analysis will be conducted for the primary outcome given the non-inferiority design. Trial result will be primarily interpreted based on ITT analysis.

研究类型

介入性

注册 (估计的)

56

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Wenjie Zheng, M.D.

研究联系人备份

学习地点

      • Beijing、中国
        • 招聘中
        • Peking Union Medical College Hospital
        • 接触:
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100730
        • 尚未招聘
        • Peking Union Medical College Hospital
        • 接触:
          • Wenjie Zheng, M.D.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Refer to the consensus on the diagnosis and treatment of intestinal Behçet's syndrome in China: Patients who meet the 2013 International Criteria for Behçet's Disease (ICBD) and have typical Behçet's syndrome-related intestinal ulcers confirmed by colonoscopy, or patients diagnosed according to the criteria for Behçet's syndrome established by the Korean Behçet's Disease Collaborative Group in 2009;
  2. Patients have a DAIBD score ≥ 40 points or intestinal symptom score ≥ 3 points at baseline;
  3. Endoscopic examination conducted within 60 days before inclusion suggests active intestinal ulcers;
  4. Patients who have been treated with medium to high-dose steroids (prednisolone equivalent of 0.5-1 mg/kg/day) for more than 1 month continuously, or any immunomodulator/Immunosuppressants for more than 3 months regularly or biologics for more than 2 months, as judged by the doctor to be treatment failure or intolerance;
  5. Currently steroid dose ≤ 30 mg prednisolone equivalent, stabilized for ≥ 2 weeks, and/or stabilized immunomodulator dose for ≥ 4 weeks;
  6. Understanding the research process, voluntary participation, and signing of informed consent.

Exclusion Criteria:

  1. Diagnosis of other diseases such as Crohn's disease, ulcerative colitis, lymphoma, etc.;
  2. Other active organ damage related to BS requires intensified immunosuppressive therapy, including aneurysms, uveitis, and substantial involvement of the central nervous system; skin lesions and joint involvement can be included;
  3. Severe organ dysfunction including ALT, AST, TBIL levels exceeding twice the upper limit of normal, creatinine levels exceeding 1.5 times the upper limit of normal, white blood cell count < 3×10^9/L, ANC < 2×10^9/L, hemoglobin < 80g/L, platelets < 100×10^9/L;
  4. Active infections such as active tuberculosis, active hepatitis B or C, syphilis, chronic Epstein-Barr virus infection, HIV infection, sustained or severe bacterial or viral infections, and history of severe herpes zoster;
  5. Patients with latent tuberculosis must undergo ≥3 weeks of prophylactic anti-tuberculosis treatment before inclusion;
  6. Primary immunodeficiency disease;
  7. History of cancer, or endoscopic intestinal histopathology indicating intraepithelial neoplasia or malignancy, or presence of other malignancies;
  8. Patients who did not respond to infliximab treatment for primary refractory BS (patients with secondary failure, intolerance, or allergy to infliximab should be included);
  9. Patients treated with biologics/small molecule targeting therapies within 5 half-lives (including use of tofacitinib within 10 days, etanercept within 4 weeks, infliximab within 8 weeks, golimumab, certolizumab, abatacept, and tocilizumab within 10 weeks, ustekinumab within 6 months);
  10. Patients with prior use of baricitinib or ADA;
  11. Complications of intestinal BS such as symptomatic stenosis, short bowel syndrome, intestinal fistula, or suspected intra-abdominal abscess; potential need for surgery or situations not conducive to DAIBD and efficacy assessment; any form of intestinal resection or other abdominal surgery within 6 months before baseline; presence of a functioning (i.e., patent) stoma or ostomy;
  12. Patients requiring parenteral nutrition due to disease severity;
  13. Pregnant, lactating, or planning pregnancy soon;
  14. Patients unwilling or unable to comply with regular visits;
  15. History of severe thrombotic events or chronic cardiovascular events.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Bariticinib用于IBS

Participants randomized to this arm will maintain their original steroids and/or immunomodulators, combined with Baricitinib 4 mg/day for 6 months.

其他名称:
  • Olumiant®
实验性的:IBS的Adalimumab

Participants randomized to this arm will maintain their original steroids and/or immunomodulators, combined with ADA (initially ADA 160 mg subcutaneous injection, followed by 80 mg ADA after 2 weeks, then 40 mg ADA every 2 weeks thereafter) for 6 months.

其他名称:
  • 修美乐®

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Proportion of patients with marked improvement (MI) at week 24 of follow-up
大体时间:Baseline to week 24

Based on the combined assessment of gastrointestinal symptoms and endoscopy scores[1], gastrointestinal symptom scoring is defined as follows: 0 points, asymptomatic; 1 point, does not affect daily life; 2 points, mildly affects daily life; 3 points, moderately affects daily life; 4 points, severely affects daily life. Endoscopy scoring is defined as follows: 0 points, mucosal healing; 1 point, maximum ulcer ≤ original 1/4; 2 points, maximum ulcer between original 1/4 and 1/2; 3 points, maximum ulcer ≥ original 1/2 or enlargement. Marked improvement is defined as gastrointestinal symptom and endoscopy scores both ≤ 1.

[1]Sugimura, N. et al. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease. Dig. Liver Dis. 51, 967-971 (2019).

Baseline to week 24

次要结果测量

结果测量
措施说明
大体时间
与随访的第24周相比,胃肠道症状评分≥1点的患者比例
大体时间:基线到第24周
基线到第24周
Proportion of patients with CR (complete response) at week 24 of follow-up
大体时间:Baseline to week 24

CR is defined as both gastrointestinal symptoms and endoscopy scores being 0.

Baseline to week 24
Changes in C-reactive protein (CRP) compared to baseline
大体时间:Baseline to week 24

The hs-CRP is acute phase reactants that are indicative of the patient's disease activity.

Baseline to week 24
Changes in erythrocyte sedimentation rate (ESR) compared to baseline
大体时间:Baseline to week 24

The ESR is acute phase reactants that are indicative of the patient's disease activity.

Baseline to week 24
Changes in DAIBD scores compared to baseline
大体时间:Baseline to week 24

Disease Activity Index for Intestinal Behcet's Disease (DAIBD);

Baseline to week 24
Changes in BDCAF scores compared to baseline
大体时间:Baseline to week 24

Behçet's Disease Current Activity Index (BDCAF);

Baseline to week 24
Changes in SF-36 of life questionnaires compared to baseline
大体时间:Baseline to week 24

Short Form (36) Health Survey(SF-36);

Baseline to week 24
Changes in IBDQ quality of life questionnaires compared to baseline
大体时间:Baseline to week 24

Inflammatory Bowel Disease Questionnaire (IBDQ)

Baseline to week 24
Incidence of Treatment-Emergent Adverse Events
大体时间:Baseline to week 24

Record the types, frequency, and severity of adverse events, as well as the number of study participants who were drop out due to any adverse events. Adverse event: Any medical condition that affects the health of the participant during the study or worsens a preexisting medical condition, regardless of whether it is causally related to the study, is considered an adverse event.

This can be symptoms, signs, or abnormal laboratory tests. Serious adverse event (SAE): Any significant medical event that causes death, is life-threatening, requires hospitalization, results in permanent or severe disability or loss of function, or the investigator deems it a significant medical event that may seriously harm the participant or require medical intervention to prevent the above outcomes.

The causal relationship between the serious adverse event and the study is determined by the investigator's discussion.

Baseline to week 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年11月8日

初级完成 (估计的)

2027年6月30日

研究完成 (估计的)

2028年6月30日

研究注册日期

首次提交

2024年7月31日

首先提交符合 QC 标准的

2025年2月23日

首次发布 (实际的)

2025年2月27日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月17日

最后验证

2026年6月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅